Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: A survey of haemophilia healthcare professionals in the United States

Haemophilia

Volumn 18, Issue 4, 2012, Pages 568-574

  Thornburg, C D ^a   Carpenter, S ^b   Zappa, S ^c   Munn, J ^d   Leissinger, C ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

^c Cook Children's Medical Center ^*  (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Haemarthrosis; Haemophilia; Prophylactic treatment; Treatment adherence

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILD CARE; FAMILY HISTORY; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIC ARTHROPATHY; HUMAN; NURSE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PEDIATRIC NURSE PRACTITIONER; PERSONALIZED MEDICINE; PHYSICIAN; PRESCHOOL CHILD; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; SCHOOL CHILD; SECONDARY PREVENTION; UNITED STATES;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; COAGULANTS; FACTOR VIII; HEALTH SURVEYS; HEMARTHROSIS; HEMOPHILIA A; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MEDICATION ADHERENCE; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; UNITED STATES;

EID: 84863186626     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02756.x     Document Type: Article

References (27)

1. Butler RB, McClure W, Wulff K. Practice patterns in haemophilia A therapy - a survey of treatment centres in the United States. Haemophilia 2003; 9: 549-54.
2. Kisker CT, Eisberg A, Schwartz B. Prophylaxis in factor IX deficiency product and patient variation. Haemophilia 2003; 9: 279-84.
3. Nilsson I, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Int Med 1992; 232: 25-32.
4. Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003; 9: 272-8.
5. Fischer K, van der Bom JG, Molho P et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-52.
6. van den Berg HM, Fischer K, van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia 2003; 9(Suppl 1): 27-31.
7. Fischer K, Van Den Berg M. Prophylaxis for severe haemophilia: clinical and economical issues. Haemophilia 2003; 9: 376-81.
8. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
9. Gringeri A, Lundin B, Mackensen SV, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
10. Thornburg CD. Physicians' perceptions of adherence to prophylactic clotting factor infusions. Haemophilia 2008; 14: 25-9.
11. Bosworth H. Medication treatment adherence. In: Bosworth H, Oddone E, Weinberger M eds. Patient Treatment Adherence: Concepts, Interventions, and Measurement. Mahweh: Lawrence Erlbaum Associates, Publishers, 2006: 158.
12. Haynes RB, Sackett DL, Gibson ES et al. Improvement of medication compliance in uncontrolled hypertension. Lancet 1976; 1: 1265-8.
13. Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA 1990; 263: 1653-7.
14. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-97.
15. Centers for Disease Control and Prevention (CDC) HTC staff database. Available at. Accessed 2010.
16. Feldman BM, Pai M, Rivard GE et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36.
17. Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010; 16: 256-62.
18. Universal Data Collection Project. Available at. Accessed 2002, 2006 and 2010.
19. Duncan N, Kronenberger W, Roberson C, Shapiro A. VERITAS-Pro: a new measure of adherence to prophylactic regimens in haemophilia. Haemophilia 2010; 16: 247-55.
20. Chan AK, Decker K, Warner M. Adherence with haemophilia treatments: a survey of haemophilia healthcare professionals in Canada. Haemophilia 2011; 17: 816-7.
21. Fischer K, Valentino L, Ljung R, Blanchette V. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors. Haemophilia 2008; 14(Suppl 3): 196-201.
22. Lindvall K, Colstrup L, Wollter IM et al. Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia. Haemophilia 2006; 12: 47-51.
23. Richards M, Altisent C, Batorova A et al. Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. Haemophilia 2007; 13: 473-9.
24. Walsh CE, Valentino LA. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia 2009; 15: 1014-21.
25. Bosworth HB, Granger BB, Mendys P et al. Medication adherence: a call for action. Am Heart J 2011; 162: 412-24.
26. du Treil S, Rice J, Leissinger CA. Quantifying adherence to treatment and its relationship to quality of life in a well-characterized haemophilia population. Haemophilia 2007; 13: 493-501.
27. Ragni MV, Fogarty PJ, Josephson NC, Neff AT, Raffini LJ, Kessler CM. Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres. Haemophilia 2012; 18: 63-8.